Get started
VIKING THERAPEUTICS INC COM USD0.00001VIKING THERAPEUTICS INC COM USD0.00001VIKING THERAPEUTICS INC COM USD0.00001

VIKING THERAPEUTICS INC COM USD0.00001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0VQA trade ideas

Here come the VikingI’ve been watching this chart for a little while now. It’s been an absolute shipwreck. I remain neutral but it’s high on my watchlist. Watching for signs of strength, we are not quite there yet. The chart reflects the lack of enthusiasm from investors, this company doesn’t generate revenue but are very close to breaking into the duopoly that is the GLP1 market, subject to their phase 3 trials. So things could change rapidly. Viking Therapeutics VKTX announced that it has initiated the phase Ill VANQUISH program, evaluating the subcutaneous (SC) formulation of its experimental obesity drug VK2735 in adult patients with or without type Il diabetes. This is bullish news. Technicals continue to look weak, the grand supercycle is over, that remains a reason not to get immediately long, wait for a sign of strength. Keep an eye on this as it could be easily do a 3-5x if their trials are successful, they’d become an acquisition target, if not even before then. Not financial advice
NASDAQ:VKTX
by NoFOMO_
VKTX – 30-Min Long Trade Setup!📈 🟢 🔹 Asset: Viking Therapeutics, Inc. (VKTX – NASDAQ) 🔹 Timeframe: 30-Min Chart 🔹 Setup Type: Symmetrical Triangle Breakout + Retest 📊 Trade Plan – Long Position ✅ Entry Zone: $23.60 (Breakout confirmation above triangle resistance) ✅ Stop-Loss (SL): $22.50 (Below structure & trendline support) 🎯 Take Profit Targets: 📌 TP1: $24.89 – Key resistance zone 📌 TP2: $26.79 – Strong supply zone 📐 Risk-Reward Calculation 🟥 Risk: $1.10/share 🟩 Reward to TP2: $3.19/share 📊 R/R Ratio: ~1 : 2.9 – Strong technical setup 🔍 Technical Highlights 📌 Breakout from triangle resistance ✔ 📌 Retest candle confirming support ✔ 📌 Trendline support intact with higher lows ✔ 📌 Momentum building with bullish candle follow-through ✔ 📉 Risk Management Strategy 🔁 Move SL to breakeven after TP1 💰 Book 50% profits at TP1 🚀 Let remainder ride toward TP2 🚨 Setup Invalidation If: ❌ Price closes below $22.50 ❌ Breakout fails with low volume ❌ Rejection near $24.00–$24.50 zone 🔗 #VKTX #BreakoutPlay #SwingTrade #NASDAQ #ProfittoPath #TrianglePattern #MomentumTrade #RiskReward #TradingView #SmartEntry
NASDAQ:VKTXLong
by ProfittoPath
VKTX – 15-Min Long Trade Setup!📈 🟢 🔹 Asset: Viking Therapeutics, Inc. (VKTX – NASDAQ) 🔹 Timeframe: 15-Min Chart 🔹 Setup Type: Symmetrical Triangle Breakout + Retest 📊 Trade Plan – Long Position ✅ Entry Zone: $22.21 (Breakout confirmation above yellow zone) ✅ Stop-Loss (SL): $21.38 (Below rising trendline + structural base) 🎯 Take Profit Targets: 📌 TP1: $23.63 – Resistance zone 📌 TP2: $25.42 – Swing high level 📐 Risk-Reward Calculation 🟥 Risk: $0.83/share 🟩 Reward to TP2: $3.21/share 📊 R/R Ratio: ~1 : 3.8 – Excellent swing play 🔍 Technical Highlights 📌 Triangle squeeze breakout on volume ✔ 📌 Structure forming higher lows + pressure build-up ✔ 📌 Clean breakout above confluence zone ✔ 📌 Breakout candle forming right at apex = strong momentum 📉 Risk Management Strategy 🔁 SL to breakeven at TP1 💰 Take partial profits at TP1 🚀 Hold remainder for full TP2 extension ⚠️ Setup Invalidation If: ❌ Price closes below $21.38 ❌ No follow-through above yellow resistance ❌ Breakdown with increasing volume 🚨 Final Thoughts ✔ Classic triangle breakout with perfect R/R ✔ Tight SL, wide reward = trader’s dream ✔ Keep watch on volume — it’s the fuel 🔗 #VKTX #BreakoutSetup #SwingTrade #ProfittoPath #ChartAnalysis #NASDAQStocks #TechnicalSetup #SmartMoney #VolumeSpike #RiskReward
NASDAQ:VKTXLong
by ProfittoPath
$VKTXyieahhh We can go touch $46 and potentially go test the upper part of the channel. Bunch of confluences for the bounce. 1. Parallel channel support 2. Wave C has same length as Wave A 2. Filled previous gap 3. Using previous high from 2023 as support 4. Weekly RSI and MACD turning around Daily RSI is in an interesting point, will reach a resistance on the daily. I want this to go back down to have another dab at this, but if it breaks we are off to the races and will hope for a retest on the RSI break. Be mindful this is another biopharma very volatile and many times news driven, which was already coincidentally this week! yieahhh
NASDAQ:VKTXLong
by rubfigue
VKTX: Bullish Divergence Leading to a Reversal?Viking Therapeutics has been in a downtrend since late 2024, with price consistently making lower lows. However, since mid January, 2025, both the Relative Strength Index (RSI) and Stochastic Momentum Index (SMI) have been sloping upward, diverging from the price action, which continued to trend lower. IMO, this bullish divergence signals that selling momentum has been weakening despite the stock's decline, and today’s 11.5% spike reinforces the idea that this setup was in play. While a single strong move doesn’t confirm a full trend reversal, the divergence leading up to it suggests that downside pressure has been fading. The key now is whether VKTX can sustain this momentum in the coming sessions. Stay tuned!
NASDAQ:VKTX
by BluntForceOptions
VIKING - To Crash, Or To Explode?VTV Therapeutics (VKTX) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat metabolic diseases. The company primarily targets areas such as non-alcoholic steatohepatitis (NASH), type 2 diabetes, and other metabolic disorders. Here's an in-depth look at the company, its position in the industry, unique aspects, developments, and market potential. As we can see from the above chart, Viking has recently broken the upper channel resistance level and its currently gone in for the re-test to confirm this level as support. However, it appears to be inching back within the channel, signalling a potential break down in price. Industry Overview: Metabolic Disease Therapies The metabolic disease market is a rapidly growing sector, driven by the increasing prevalence of conditions like type 2 diabetes, obesity, NASH, and other liver diseases. The demand for effective treatments in these areas is rising as the global population experiences higher rates of these chronic conditions. NASH, for instance, is a significant focus of research because it can lead to liver cirrhosis and liver cancer, and there are currently limited approved treatments for it. The diabetes and obesity market is also substantial, with new treatments focusing on insulin resistance, fat metabolism, and weight management in high demand. Unique Aspects of VTV Therapeutics (VKTX) 1. Selective Receptor Modulators: [/i ] One of the company’s key differentiators is its use of selective receptor modulators (SRMs), which are designed to specifically target receptors involved in metabolic diseases. This approach allows for potentially more effective treatments with fewer side effects than traditional therapies. 2. Lead Drug Candidate - VTX-800: VTV’s lead candidate is VTX-800, a small molecule selective FFAR4 receptor modulator. This drug is being developed to treat NASH and type 2 diabetes, targeting the free fatty acid receptor 4 (FFAR4), which plays a crucial role in metabolism and insulin sensitivity. In preclinical and early clinical trials, VTX-800 has demonstrated potential for improving both liver function and insulin resistance in patients. 3. Strong Pipeline: In addition to VTX-800, VTV Therapeutics has other promising compounds in its pipeline targeting type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Their approach leverages cutting-edge metabolic biology to address large, underserved markets. 4. Collaborations: The company has also entered into various collaborations with larger biopharmaceutical companies to enhance its research and development capabilities. These partnerships help strengthen its position in the competitive market for metabolic disease therapies. Recent Developments and Trials Phase 2 Clinical Trials: VTX-800 is currently in Phase 2 clinical trials for NASH and type 2 diabetes. The drug has shown promising preclinical results in both liver function and glycemic control, positioning it as a potential breakthrough in these areas. NASH Pipeline: VTV is also pursuing additional treatments for NASH, a field where there is intense competition due to the lack of approved therapies and the growing demand for effective solutions. Type 2 Diabetes Research: Their research on type 2 diabetes involves addressing insulin resistance, a major contributor to the disease. This is a massive market, with increasing incidence globally, creating significant potential for therapies that can effectively manage or reverse the condition. Current Market Cap and Financials As of December 2024, VTV Therapeutics' market cap is approximately $225 million. The company has seen fluctuating stock prices based on clinical trial results and investor sentiment regarding its drug candidates. The small market cap reflects its current stage as a clinical-stage biotech firm, with significant risk and potential rewards as it moves through its clinical trial phases. Potential Future Market Cap The future market cap of VTV Therapeutics will heavily depend on the successful progression and approval of its key drug candidates. If VTX-800 proves to be effective in Phase 3 trials for NASH or type 2 diabetes, the company’s market cap could see a substantial increase, potentially in the $1-2 billion range or higher, similar to other biotech firms that have brought successful metabolic disease drugs to market. 1. NASH Market: The NASH market alone is expected to grow to more than $20 billion by 2025, driven by rising prevalence and lack of treatment options. If VTX-800 is approved for NASH, VTV Therapeutics could capture a significant share of this market, significantly boosting its valuation. 2. Type 2 Diabetes and Obesity : As the prevalence of type 2 diabetes and obesity continues to rise globally, therapies targeting insulin resistance and metabolic function are in high demand. Successful clinical results in these areas could substantially increase VTV Therapeutics’ market cap. Conclusion VTV Therapeutics (VKTX) is a promising player in the metabolic disease space with its innovative approach to targeting diseases like NASH and type 2 diabetes. The company’s progress in clinical trials, particularly with VTX-800, positions it to potentially disrupt the metabolic disease treatment market. While its current market cap reflects the risks associated with being a clinical-stage biotech, the company has significant upside potential, particularly if its leading drug candidate achieves clinical success and gains regulatory
NASDAQ:VKTX
by Who-Is-Caerus
$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀 Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed. With more probabilities on our side, the likelihood of success is through the roof! 📈💥 Check it out, and let’s ride this wave together! 🌊 Stay tuned for more insights! 🔔 NFA #Trading #StockMarket #Biotech #Investing #HighFiveSetup
NASDAQ:VKTXLong
by RonnieV29
41
Next move in progress... This is just my personal trading setup so that I keep it in mind. Viking Therapeutics (VKTX) prepares for its next move. The following things need to happen for me to be bullish: On the 3D chart: 1. The RSI needs to move above the moving average. 2. On the RCI indicator, the mid-trend line (blue) needs to move above the long-trend line (green). 3. The chart needs to break out of its channel to the upside. If so, the next target is around $200. www.barrons.com
NASDAQ:VKTXLong
by Val-the_vagrant_Surfer
Viking Therapeutics Surges 25% Amidst Weight Loss Pill Data In a remarkable turn of events, Viking Therapeutics ( NASDAQ:VKTX ) has sent shockwaves through the pharmaceutical industry with groundbreaking results from its experimental weight loss pill. The company's shares soared by over 25% following the announcement of positive outcomes from a small-scale study, propelling it into the forefront of the fiercely competitive weight-loss drug market. Viking's innovative once-a-day oral tablet demonstrated remarkable efficacy in aiding weight loss among participants. Over 28 days, patients who received the pill experienced an average weight loss of up to 5.3%, significantly surpassing the outcomes of those who were administered a placebo. Notably, an impressive 57% of individuals treated with Viking's pill achieved a weight reduction of at least 5%, showcasing the drug's potential to revolutionize the treatment landscape for obesity. Moreover, the trial unveiled encouraging findings regarding the durability of weight loss, with patients maintaining or even augmenting their progress six days after the cessation of the medication. Viking's CEO, Brian Lian, underscored the significance of this sustained effect, particularly for patients facing challenges in adhering to a daily regimen. "I think that's an encouraging sign that you don't necessarily have to take it every day," remarked Lian during a conference call, hinting at the flexibility and convenience offered by Viking's pioneering approach. Crucially, the trial also provided reassuring insights into the safety and tolerability of the oral drug, with the majority of reported side effects being mild and transient. Unlike some existing treatments, patients did not report vomiting, while gastrointestinal events were predominantly mild in nature—a testament to Viking's commitment to developing a well-tolerated therapy. Analysts have drawn parallels between Viking's weight loss injection and established drugs like Eli Lilly's Zepbound, highlighting their shared mechanism of action in mimicking gut hormones involved in appetite regulation and metabolic control. By leveraging the synergistic effects of GLP-1 and GIP, Viking's pill offers a multifaceted approach to weight management, distinguishing itself in a rapidly evolving landscape. As the company sets its sights on advancing to phase two trials later this year, anticipation is palpable within the investment community and among patients seeking effective and accessible solutions for obesity. With the potential to tap into a burgeoning market projected to reach $100 billion by the end of the decade, Viking Therapeutics ( NASDAQ:VKTX ) stands poised to redefine the standard of care and carve out a niche as a formidable contender in the fight against obesity-related ailments. Technical Outlook Viking Therapeutics ( NASDAQ:VKTX ) Spiked more than 25% prior to the weight loss pill data news with a positive Relative Strength Index (RSI) of 65 indicating a moderately overbought solution with a potential for further surge. In an era marked by escalating rates of obesity and metabolic disorders, Viking's groundbreaking advancements offer a glimmer of hope for millions worldwide, signaling a new dawn in the quest for sustainable weight loss solutions. As the journey unfolds, all eyes remain fixed on Viking Therapeutics, a beacon of innovation and progress in the pursuit of healthier futures.
NASDAQ:VKTXLong
by DEXWireNews